Episode 19: Reflections - Eli Lilly Earnings 2Q17
S&P Global Ratings credit analyst Arthur Wong shares his thoughts on Eli Lilly's recent earnings call, including thoughts on top drug prospect, the rheumatoid arthritis treatment, baricitinib, continued sales and margin growth, pipeline challenges, and the potential for M&A, all in the context of the ratings.